You are viewing the site in preview mode
Skip to main content
| |
LZD group
| |
LZD/RFP group
| |
|---|
|
Gender (male/female)
|
4 / 3
| |
2 / 1
| |
|
Age (year)
|
60 ± 19
|
[21–82]
|
51 ± 11
|
[41–62]
|
|
Body weight (kg)
|
66.0 ± 17.2
|
[46.6–95.0]
|
57.8 ± 14.5
|
[46.0–74.0]
|
|
eGFR (mL/min/1.73 m2)
|
65.2 ± 26.3
|
[32.7–105]
|
99.9 ± 34.7
|
[65.6–135]
|
|
Baseline CRP concentration (mg/dL)
|
3.0 ± 3.1
|
[0.7–8.9]
|
1.8 ± 0.6
|
[1.2–2.4]
|
|
LZD dose and concentrations
|
|
Total dose (g)
|
14.3 ± 5.2
|
[7.2–21.0]
|
28.4 ± 9.1
|
[18.0–34.8]
|
|
Daily dose (g/day)
|
1.04 ± 0.21
|
[7.29–1.20]
|
1.20 ± 0.0
| |
|
Daily dose (mg/kg/day)
|
16.7 ± 5.7
|
[10.5–25.8]
|
21.6 ± 5.0
|
[16.2–26.1]
|
|
Duration of LZD therapy (day)
|
14 ± 6
|
[6–21]
|
24 ± 8
|
[15–29]
|
|
Number of TDM
|
21
| |
13
| |
|
Trough concentration at first assessment day (μg/mL)
|
13.3 ± 8.4
|
[4.7–29.4]
|
6.9 ± 5.0
|
[2.1–12.1]
|
|
C/D ratio at first assessment day (μg/mL/mg/kg/day)
|
0.83 ± 0.46
|
[0.32–1.34]
|
0.29 ± 0.17
|
[0.13–0.47]
|
|
Patients with dosage adjustments to avoid overexposure, n (%)
|
3 (42.9%)
| |
0 (0%)
| |
|
CRP concentration at first assessment day (mg/dL)
|
4.2 ± 4.6
|
[0.3–13.8]
|
2.0 ± 2.0
|
[0.7–4.3]
|
|
Hematological adverse effects
|
|
Baseline platelet count (106 platelets/μL)
|
266 ± 88
|
[174–445]
|
325 ± 128
|
[189–443]
|
|
Nadir platelet count (106 platelets/μL)
|
150 ± 82
|
[86–320]
|
173 ± 113
|
[69–293]
|
|
Thrombocytopenia, n (%)
|
4 (57.1%)
| |
1 (33.3%)
| |
|
Baseline Hb (g/dL)
|
9.6 ± 1.8
|
[7.3–12.9]
|
11.4 ± 1.2
|
[10.1–12.2]
|
|
Nadir Hb (g/dL)
|
8.9 ± 2.2
|
[6.8–12.8]
|
10.4 ± 2.8
|
[7.1–12.1]
|
|
Anemia, n (%)
|
3 (42.9%)
| |
1 (33.3%)
| |
|
Outcomes
|
|
Success, n (%)
|
5 (71.4%)
| |
3 (100%)
| |
- C/D ratio dose-normalized trough concentration, Hb hemoglobin, eGRF estimated glomerular filtration rate, CRP C-reactive protein
